182822-62-4 Usage
Uses
Used in Pharmaceutical Industry:
Rel-N-[4-Methoxy-3-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]phenyl]-N-methyl-methanesulfonamide is used as a neurokinin-1 (NK1) receptor antagonist for its potential role in treating conditions related to the central nervous system. It exhibits potent and selective antagonistic activity against the NK1 receptor, which is involved in various physiological processes and disorders.
Used in Research and Development:
In the field of research and development, Rel-N-[4-Methoxy-3-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]phenyl]-N-methyl-methanesulfonamide serves as a valuable tool for studying the function and role of the NK1 receptor in the body. It can be used to investigate the mechanisms of action of neurokinin receptors and their potential as therapeutic targets for various diseases and conditions.
Used in Drug Design and Optimization:
Rel-N-[4-Methoxy-3-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]phenyl]-N-methyl-methanesulfonamide can be utilized in the design and optimization of new drugs targeting the NK1 receptor. Its unique chemical structure and receptor binding properties make it a promising starting point for the development of more effective and selective NK1 receptor antagonists.
Check Digit Verification of cas no
The CAS Registry Mumber 182822-62-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,2,8,2 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 182822-62:
(8*1)+(7*8)+(6*2)+(5*8)+(4*2)+(3*2)+(2*6)+(1*2)=144
144 % 10 = 4
So 182822-62-4 is a valid CAS Registry Number.
InChI:InChI=1/C21H29N3O3S/c1-24(28(3,25)26)18-11-12-20(27-2)17(14-18)15-23-19-10-7-13-22-21(19)16-8-5-4-6-9-16/h4-6,8-9,11-12,14,19,21-23H,7,10,13,15H2,1-3H3/t19-,21-/m0/s1
182822-62-4Relevant academic research and scientific papers
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist
Rosen, Terry J.,Coffman, Karen J.,McLean, Stafford,Crawford, Rosemary T.,Bryce, Dianne K.,Gohda, Yoshiko,Tsuchiya, Megumi,Nagahisa, Atsushi,Nakane, Masami,Lowe III, John A.
, p. 281 - 284 (2007/10/03)
The synthesis and SAR of benzylamine side chain analogs of the NK-1 receptor antagonist CP-99,994 are described. The 5-trifluoromethoxy analog, CP-122,721, shows superior in vivo blockade of NK-1 receptor mediated responses.
Substituted benzylamino nitrogen containing non-aromatic heterocycles
-
, (2008/06/13)
The present invention relates to novel substituted benzylamino nitrogen containing non-aromatic heterocycles and, specifically, to compounds of the formula STR1 wherein W, R1, R2, R3 and A are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
